Literature DB >> 21057841

Scintigraphic, neuroradiological and clinical comparison in two patients with primary sporadic and two with secondary Fahr's disease.

Giovanni Caranci1, Giovanni Grillea, Francesco Barbato, Alexandra Brunetti, Tiziana Tassinari, Mariarita Di Ruzza, Francesco Lena, Barbara Gandolfi, Anna Elisa Castellano, Marcello Bartolo, Claudio Colonnese, Nicola Modugno, Stefano Ruggieri, Mario Manfredi.   

Abstract

Bilateral striopallidodentate calcification, usually termed Fahr's disease, can give rise to various clinical manifestations including hyperkinetic movement disorders or a hypokinetic Parkinsonian syndrome, behavioural and mood changes, cognitive deficits and even frank dementia. We describe four patients all of whom underwent a detailed scintigraphic, neuroradiological and clinical work-up: two had primary, sporadic Fahr's disease and two had Fahr's disease secondary to hypoparathyroidism. The neuroradiological and clinical studies disclosed similar anatomical and pathological changes in the four patients but variable and sometimes unexpected clinical manifestations. Both patients with primary forms had hypokinetic Parkinsonian syndrome, both patients with secondary forms had hyperkinetic movements. Dopamine autotransporter scan brain scintigraphy disclosed an unexpected unilateral putamen involvement despite substantially symmetric calcifications.

Entities:  

Mesh:

Year:  2010        PMID: 21057841     DOI: 10.1007/s10072-010-0444-9

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  15 in total

Review 1.  Bilateral striopallidodentate calcinosis: clinical characteristics of patients seen in a registry.

Authors:  B V Manyam; A S Walters; K R Narla
Journal:  Mov Disord       Date:  2001-03       Impact factor: 10.338

2.  Imaging of bilateral striopallidodentate calcinosis.

Authors:  Shigeyuki Ogi; Nobuyoshi Fukumitsu; Daisuke Tsuchida; Mayuki Uchiyama; Yutaka Mori; Kazutaka Matsui
Journal:  Clin Nucl Med       Date:  2002-10       Impact factor: 7.794

3.  Elevated cerebrospinal fluid lactate levels and the pathomechanism of calcification in Fahr's disease.

Authors:  N Hagiwara; H Ooboshi; M Ishibashi; H Kurushima; T Kitazono; S Ibayashi; M Iida
Journal:  Eur J Neurol       Date:  2006-05       Impact factor: 6.089

4.  Evaluation of regional cerebral blood flow in massive intracerebral calcifications.

Authors:  G A Uygur; Y Liu; R S Hellman; R S Tikofsky; B D Collier
Journal:  J Nucl Med       Date:  1995-04       Impact factor: 10.057

5.  Calcification of the basal ganglia as a cause of levodopa-resistant parkinsonism.

Authors:  H L Klawans; M Lupton; L Simon
Journal:  Neurology       Date:  1976-03       Impact factor: 9.910

6.  The chemical composition of idiopathic nonarteriosclerotic cerebral calcifications.

Authors:  J Smeyers-Verbeke; Y Michotte; J Pelsmaeckers; A Lowenthal; D L Massart; D Dekegel; D Karcher
Journal:  Neurology       Date:  1975-01       Impact factor: 9.910

7.  Fahr's syndrome presenting with pure and progressive presenile dementia.

Authors:  P J Modrego; J Mojonero; M Serrano; N Fayed
Journal:  Neurol Sci       Date:  2005-12       Impact factor: 3.307

8.  Subacute dementia and imaging correlates in a case of Fahr's disease.

Authors:  T Benke; E Karner; K Seppi; M Delazer; J Marksteiner; E Donnemiller
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-08       Impact factor: 10.154

Review 9.  Frontal-subcortical circuits and neuropsychiatric disorders.

Authors:  M S Mega; J L Cummings
Journal:  J Neuropsychiatry Clin Neurosci       Date:  1994       Impact factor: 2.198

10.  Technetium-99m HMPAO imaging in patients with basal ganglia disease.

Authors:  F W Smith; H G Gemmell; P F Sharp; J A Besson
Journal:  Br J Radiol       Date:  1988-10       Impact factor: 3.039

View more
  1 in total

1.  Brain structural and functional abnormalities in Fahr's disease: a report of two cases.

Authors:  Roberta Messina; Maria A Rocca; Bruno Colombo; Andrea Falini; Giancarlo Comi; Massimo Filippi
Journal:  J Neurol       Date:  2013-06-05       Impact factor: 4.849

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.